Literature DB >> 20670046

Idiopathic breakthrough pain: a new hypothesis.

Alessandro Fabrizio Sabato1.   

Abstract

Breakthrough pain (BTP) in treated patients with chronic pain states is neither well defined nor well understood. BTP is generally defined as a transient exacerbation of pain experienced by a patient with relatively stable and adequately controlled baseline pain. It is usually categorized as spontaneous, with no known cause, or incident, when initiated by voluntary or involuntary movements, or therapeutic procedures. Since pain is related to survival, it possibly cannot be completely and permanently controlled. It is hypothesized that glia are at least partially responsible for inducing pain spikes by attempting to reactivate unresponsive neurons. Therefore, compounds that modulate microglia may offer potential alternative therapeutic options in the control of idiopathic BTP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20670046     DOI: 10.2165/1158410-S0-000000000-00000

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  21 in total

Review 1.  Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care.

Authors:  Sebastiano Mercadante; Lukas Radbruch; Augusto Caraceni; Nathan Cherny; Stein Kaasa; Friedemann Nauck; Carla Ripamonti; Franco De Conno
Journal:  Cancer       Date:  2002-02-01       Impact factor: 6.860

Review 2.  Nerve growth factor: from neurotrophin to neurokine.

Authors:  R Levi-Montalcini; S D Skaper; R Dal Toso; L Petrelli; A Leon
Journal:  Trends Neurosci       Date:  1996-11       Impact factor: 13.837

3.  Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation.

Authors:  Annemarie Ledeboer; Evan M Sloane; Erin D Milligan; Matthew G Frank; John H Mahony; Steven F Maier; Linda R Watkins
Journal:  Pain       Date:  2005-05       Impact factor: 6.961

4.  The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.

Authors:  Sebastiano Mercadante; Patrizia Villari; Patrizia Ferrera; Salvatore Mangione; Alessandra Casuccio
Journal:  Clin J Pain       Date:  2010-05       Impact factor: 3.442

5.  Recent development in therapeutics for breakthrough pain.

Authors:  Mellar P Davis
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

6.  Breakthrough pain: definition, prevalence and characteristics.

Authors:  Russell K Portenoy; Neil A Hagen
Journal:  Pain       Date:  1990-06       Impact factor: 6.961

Review 7.  Pain mechanisms and management: a central perspective.

Authors:  R J Mannion; C J Woolf
Journal:  Clin J Pain       Date:  2000-09       Impact factor: 3.442

8.  Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization.

Authors:  Zhi-Ye Zhuang; Haoxing Xu; David E Clapham; Ru-Rong Ji
Journal:  J Neurosci       Date:  2004-09-22       Impact factor: 6.167

Review 9.  Pathological and protective roles of glia in chronic pain.

Authors:  Erin D Milligan; Linda R Watkins
Journal:  Nat Rev Neurosci       Date:  2009-01       Impact factor: 34.870

Review 10.  Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness.

Authors:  Joanna Mika
Journal:  Pharmacol Rep       Date:  2008 May-Jun       Impact factor: 3.024

View more
  2 in total

1.  Canadian recommendations for the management of breakthrough cancer pain.

Authors:  P Daeninck; B Gagnon; R Gallagher; J D Henderson; Y Shir; C Zimmermann; B Lapointe
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

2.  Role of mesotherapy in musculoskeletal pain: opinions from the italian society of mesotherapy.

Authors:  Massimo Mammucari; Antonio Gatti; Sergio Maggiori; Alessandro F Sabato
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-13       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.